Diamonds and Dogs
8/14/13Cree Inc. (CREE)
Cree Inc. isn't shining today, down 22.24% at $58.91. The LED light company saw its shares fall after releasing new guidance for the first quarter of 2014. Cree management announced it expects to collect revenues between $380 million and $400 million. At the midpoint, that is short of the $399 million that analysts are expecting. The company also promised to earn profits of between $0.36 and $0.41 per share in Q1, which also was short of analyst expectations of $0.43. Cree shares lost nearly $17.00 today, but are still trading in their 52-week range of $24.50-$76.00.
Ampio Pharmaceuticals Inc. (AMPE)
Ampio Pharmaceuticals is trading in the green today, up 15.30% at $6.18. The biopharmaceutical company saw its shares jump after positive news in its SPRING trial regarding osteoarthritis in the knee. In this study of 329 patients, patients treated with a single intra-articular injection of Ampion achieved a clinically meaningful reduction in pain. The primary study objective was to evaluate the relative efficacy of Ampion 4 mL versus Ampion 10 mL. There were no drug-related serious adverse events. Selection of the optimal dose for the second Phase 3 trial will be decided in consultation with the FDA. Ampio shares climbed up near their 52-week high of $7.17, reaching $6.99 intraday.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.